We begin this week with a short interview with Bashir Hansraj – formerly head of Research and Development at Catalent - who takes on the role of Technical Director for Aesica’s new Lead Technical Centres for API development, drug product development and technology innovation.
Outsourcing-Pharma.com asked Hansraj what the biggest problem facing the contract manufacturing industry was at present.
He said: “Some CMOs lack the flexibility to meet the varied capacity needs of customers or to offer a one-stop-shop comprehensive service offering across API, formulation development and formulated product services with consistent and high standards of technological excellence across all such services.”
Aesica is staying ahead of the game by “offering extensive and fully integrated services,” he added. “Our Lead Technical Centres represent the latest step in our best in class approach to technological servicing of customer needs.”
Furthermore Hansraj said his new role is his ideal position: “Leading technical and innovation strategies across API and dosage forms plays to my key strengths and I now have a terrific opportunity to provide leadership of high performing, global, technically focused teams.”
And Aesica spoke to us recently regarding its strategy to offer cheaper, greener amide bonds. Read about it here.
This Advanced Delivery Technologies Unit will operate across Catalent’s global network and will be headed up by Barry Littlejohns who has over 25 years of experience in drug delivery. Formerly President of Medication Delivery Solutions at Catalent, Littlejohns becomes President of the new Unit.
ADC Bio has been receiving a number of financial boosts in recent months as pharma demand for antibody drug conjugates skyrockets, and the firm has added a new Business Development Manager to support the growing operations.
Pam Cumberbirch, with a 15-year track record in Pharma/biotech CMO key account management, will take on the role. She has previously worked for Zeneca CRB, Avecia Biotechnology and CARBOGEN-AMCIS.
“Pam’s deep experience in biotech key account management marks an important addition to our service capability,” said CEO Charlie Johnson.
And finally this week, Tissue Solution – a firm who provides tissue for preclinical drug and safety testing – has appointed Dr. Derek McFerran as Business Development Director.
McFerran has spent the last five years at cytokines manufacturer, PeproTech, and has spent more than 15 years in the biomanufacturing and drug discovery industry.
Also at the firm, Dr. Fiona Mackenzie, who has spent three years as Senior Executive Scientist, will become the new Client Service Director.